Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 6/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 6/20 | 0.43 |
| ▸ | ESR1 | P03372 | 5/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.43 |
| ▸ | RARA | P10276 | 3/20 | 0.42 |
| ▸ | RARG | P13631 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL616344 | 0.89 | RARA (0.46) | TYRESR1ESR2RARARARG | |
| Idronoxil SCHEMBL29353213 | 0.85 | ESR2 (0.49) | TYRESR1ESR2RARARARG | |
| Idronoxil SCHEMBL149612 | 0.85 | ESR2 (0.49) | TYRESR1ESR2RARARARG | |
| SCHEMBL614571 | 0.84 | NR1H4 (0.51) | TYRRARARARGCYP3A4CYP2C9 | |
| SCHEMBL4183249 | 0.80 | HSD17B1 (0.38) | TYRHSD17B1HSD17B2ESR1ESR2 | |
| SCHEMBL615450 | 0.79 | TYR (0.43) | TYRESR1ESR2RARARARG | |
| SCHEMBL676933 | 0.79 | TYR (0.45) | TYRESR1ESR2RARARARG | |
| SCHEMBL615914 | 0.77 | HSD17B1 (0.41) | TYRHSD17B1HSD17B2ESR1ESR2 | |
| SCHEMBL616710 | 0.77 | RARA (0.49) | TYRRARARARGRARBNR1H4 | |
| SCHEMBL4320833 | 0.77 | TYR (0.57) | TYRESR1ESR2RARARARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906660-B2 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-15 | — | — | US | claimed |
| US-20060217564-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2006-09-28 | — | — | US | claimed |
| US-8367659-B2 | Oxazinyl isoflavonoid compounds, medicaments and use | MARSHALL EDWARDS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120039917-A1 | IMMUNOMODULATING ACTIVITIES | MARSHALL EDWARDS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120003270-A1 | 6-SUBSTITUTED ISOFLAVONOID COMPOUNDS AND USES THEREOF | MARSHALL EDWARDS, INC. | 2012-01-05 | — | — | US | disclosed |
| EP-2125831-B1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | NOVOGEN RES PTY LTD (AU) | 2011-12-28 | — | — | EP | disclosed |
| EP-2324003-A1 | 6-SUBSTITUTED ISOFLAVONOID COMPOUNDS AND USES THEREOF | Novogen Research Pty Ltd (AU) | 2011-05-25 | — | — | EP | disclosed |
| US-7906554-B2 | Combination chemotherapy compositions and methods | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-15 | — | — | US | disclosed |
| US-7906554-B2 | Combination chemotherapy compositions and methods | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-15 | — | — | US | disclosed |
| US-7906660-B2 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD (AU) | 2011-03-15 | — | — | US | disclosed |
| US-20110046722-A1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | NOVOGEN RESEARCH PTY LTD (AU) | 2011-02-24 | — | — | US | disclosed |
| WO-2008106715-A1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | NOVOGEN RESEARCH PTY LTD (AU) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008052256-A1 | PREVENTION AND REVERSAL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY | NOVOGEN RESEARCH PTY LTD (AU) | 2008-05-08 | — | — | WO | disclosed |
| US-20080069900-A1 | Combination chemotherapy compositions and methods | NOVOGEN RESEARCH PTY LTD | 2008-03-20 | — | — | US | disclosed |
| US-20080069900-A1 | Combination chemotherapy compositions and methods | NOVOGEN RESEARCH PTY LTD | 2008-03-20 | — | — | US | disclosed |
| US-20060217564-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2006-09-28 | — | — | US | disclosed |
| US-20050143588-A1 | Production of isoflavone derivatives | NOVOGEN RESEARCH PTY LTD. | 2005-06-30 | — | — | US | disclosed |
| EP-1153020-A4 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RES PTY LTD (AU) | 2002-08-21 | — | — | EP | disclosed |
| EP-1153020-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | Novogen Research Pty. Ltd. (AU) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049009-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RESEARCH PTY. LTD. (AU) | 2000-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217564-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | TYR 2129/4885HSD17B1 77/4885HSD17B2 68/4885 |
| US-20120039917-A1 | IMMUNOMODULATING ACTIVITIES | CD4, NFATC1, HRH2 | TYR 699/4885HSD17B1 45/4885HSD17B2 69/4885 |
| US-20110046722-A1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | TNNI3, NFE2L2, OAT | TYR 2848/4885HSD17B1 192/4885HSD17B2 142/4885 |
| US-20050143588-A1 | Production of isoflavone derivatives | CYP51A1, EGLN2, EGLN3 | TYR 2129/4885HSD17B1 77/4885HSD17B2 68/4885 |
| US-20080069900-A1 | Combination chemotherapy compositions and methods | TOP2A, IDH2, DHFR | TYR 4744/4885HSD17B1 1566/4885HSD17B2 1076/4885 |
| US-20120003270-A1 | 6-SUBSTITUTED ISOFLAVONOID COMPOUNDS AND USES THEREOF | UGT1A6, CYP19A1, HSD17B11 | TYR 179/4885HSD17B1 92/4885HSD17B2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.